Product Description: Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8./[2]Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22.
CAS Number: 400010-39-1
Molecular Weight: 150000 (average)
Compound Purity: 96.02
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin
English
Deutsch
